SB
@farmerboy
https://www.medscape.com/viewarticle/new-data-glp-1-ras-and-psychiatric-side-effects-2025a1000cu8?ecd=WNL_trdalrt_CS4_pos3_250526_etid7451050&uac=122484SX&impID=7451050 Treatment with glucagon-like peptide 1 receptor agonists (GLP-1 RAs) for weight loss or diabetes management doesn ’t raise the risk for adverse psychiatric events and improves quality of life (QOL) in people with no history of mental illness, a large new review has found.
0 reply
0 recast
1 reaction